Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 4.1% – Should You Buy?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shares rose 4.1% on Thursday . The company traded as high as $26.00 and last traded at $25.95. Approximately 133,351 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 418,630 shares. The stock had previously closed at $24.93.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wedbush raised their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $33.60.

Kiniksa Pharmaceuticals Trading Up 4.2 %

The firm’s fifty day moving average is $25.36 and its 200-day moving average is $21.71. The stock has a market capitalization of $1.89 billion, a PE ratio of -165.99 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The firm had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same period in the prior year, the business posted ($0.02) EPS. The business’s revenue for the quarter was up 51.5% compared to the same quarter last year. As a group, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current year.

Insider Activity

In other news, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanj K. Patel sold 136,124 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the transaction, the chief executive officer now owns 63,012 shares of the company’s stock, valued at approximately $1,616,257.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 278,064 shares of company stock valued at $7,165,254. 54.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth about $71,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $100,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after acquiring an additional 3,611 shares during the last quarter. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $177,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.